US Equities Lead Global Markets Amidst Middle East Tensions
Finance

US Equities Lead Global Markets Amidst Middle East Tensions

authorBy Fareed Zakaria
DateJun 29, 2026
Read time1 min

In the wake of recent geopolitical events in the Middle East, a significant divergence in financial market performance has become apparent, with US equities demonstrating a clear leadership position. While experts continue to assess the broader geopolitical ramifications, the behavior of global asset prices provides a compelling narrative of American economic resilience and market dominance.

An examination of various asset classes, as represented by their respective Exchange Traded Funds (ETFs), highlights that American stock markets have outperformed their global counterparts. This robust performance of US stocks is particularly noteworthy given the backdrop of heightened international tensions. This trend suggests that investors perceive the US market as a safe haven or a beneficiary of the current global economic landscape, further solidifying its standing in times of uncertainty.

The sustained strength of American equities in a volatile global environment underscores the nation's economic stability and adaptability. This performance not only reflects investor confidence in the US economy but also emphasizes the potential for growth and resilience that continues to attract capital from around the world. In an interconnected world, the ability of the US market to lead during periods of geopolitical flux sends a powerful message of its enduring appeal and fundamental strength.

More Articles
Finance
Riot Platforms: Navigating the AI Narrative and Market Realities
This article examines Riot Platforms' recent foray into AI infrastructure, highlighting the initial one-time nature of its data center revenue. It questions the significant stock price appreciation, suggesting it's driven more by speculative AI narratives than by concrete, sustained operational proof. The analysis emphasizes that while the company has made strides in launching new IT capacity, a substantial portion of its contracts remains pending, leading to a cautionary outlook for investors who might be overpricing the stock based on these early, yet unproven, signals of AI transformation.
By Morgan HouselJun 29, 2026
Finance
Why Meta Platforms' Stock Is a Must-Have Investment: A Deep Dive into Its Valuation and AI Strategy
Meta Platforms, Inc. (META) is a compelling 'Strong Buy' for Q3 due to its significant share repricing and attractive valuation compared to other 'Magnificent Seven' stocks. Despite market bleeding, Meta trades at the lowest near-term forward earnings multiples, with FY1 non-GAAP P/E at 17.1x and forward EV/EBITDA at 9.67x. Concerns about capital expenditure are overstated, as the company's AI infrastructure investments are strategic, aiming to reduce external provider reliance and unlock new monetization avenues through proprietary AI models, consumer AI agents, and potential external infrastructure monetization.
By Suze OrmanJun 29, 2026
Finance
Top GMAT Preparation Programs for Aspiring Business Leaders
Choosing the right GMAT prep course is crucial for admission to top business schools. This article reviews leading GMAT preparation providers, evaluating them based on factors like course content, pricing, study resources, and score improvement guarantees. Whether you prefer self-study, live instruction, or personalized tutoring, this guide helps you find the ideal program to maximize your GMAT score.
By David RubensteinJun 29, 2026
Finance
Market Optimism Amidst Geopolitical Tensions: Stocks Rebound, Oil Prices Edge Higher
Markets witnessed an upward trend in the initial trading hours of a shortened week, recovering from previous downturns and geopolitical anxieties. This surge is notable as the quarter and first half of the year draw to a close, with investors closely monitoring key economic indicators and corporate announcements.
By Suze OrmanJun 29, 2026
Finance
Tonix Pharmaceuticals: Navigating Challenges with Tonmya Launch and Pipeline Prospects
Tonix Pharmaceuticals faces an uphill battle as its fibromyalgia drug, Tonmya, experiences a slow commercial start, with Q1 2026 net product revenue falling short of expectations. The company's limited cash reserves and ongoing net losses raise concerns about future funding. While competitive pressures and uncertainties surrounding its pipeline candidates for MDD and Lyme disease temper optimism, the stock maintains a 'Hold' rating due to potential, albeit distant, upside from accelerated Tonmya sales or positive pipeline data.
By Nouriel RoubiniJun 29, 2026